{
    "organizations": [],
    "uuid": "95f6d6ae623b54cb4db850c1100ba2ca6d11ecb1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-fy-result-sw/brief-cosmo-pharmaceuticals-fy-result-swings-to-loss-of-eur-32-5-million-idUSFWN1R7016",
    "ord_in_thread": 0,
    "title": "BRIEF-Cosmo Pharmaceuticals FY Result Swings To Loss Of EUR 32.5 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - COSMO PHARMACEUTICALS NV:\n* FY REVENUE EUR 67.2 MILLION VERSUS EUR 67.7 MILLION IN 2016\n* FY LOSS AFTER TAX OF EUR 32.5 MILLION, INCLUDING FX LOSS OF EUR 18.7 MILLION ON OUR US$ LIQUIDITY POSITION\n* SEES OPERATING LOSS OF APPROX EUR 40 MILLION IN 2018 BEFORE WE EXPECT TO RETURN TO PROFIT IN 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-26T13:10:00.000+03:00",
    "crawled": "2018-03-27T11:57:51.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "cosmo",
        "pharmaceutical",
        "nv",
        "fy",
        "revenue",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "fy",
        "loss",
        "tax",
        "eur",
        "million",
        "including",
        "fx",
        "loss",
        "eur",
        "million",
        "u",
        "liquidity",
        "position",
        "see",
        "operating",
        "loss",
        "approx",
        "eur",
        "million",
        "expect",
        "return",
        "profit",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}